Reports Q2 revenue $224,000, consensus $3.38M. “The updated data we presented at EHA this past quarter were highly encouraging and supportive of the therapeutic potential of divesiran as a first-in-class siRNA in PV,” said Craig Tooman, President and Chief Executive Officer at Silence. “The SANRECO Phase 2 trial of divesiran in PV patients continues to progress towards full enrollment this year and remains our top priority.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLN:
- Silence Therapeutics Passes Key Resolutions at AGM
- Buy Rating on Silence Therapeutics: Promising Developments in Divesiran and Zerlasiran Programs
- Promising Phase 1 Data and Strong Mechanistic Rationale Justify Buy Rating for Silence Therapeutics’ Divesiran in Polycythemia Vera
- Positive Outlook for Silence Therapeutics: Promising Clinical Data and Progress in SANRECO Study Justify Buy Rating
- Silence Therapeutics presents additional Phase 1 data highlighting Divesiran